AIPA-Karnataka observes first anniversary of its formation focuses on ADR and AMR: Our Bureau, Bengaluru Friday, January 23, 2026, 14:50 Hrs [IST] All India Government Private and ...

NABL issues guidance on specific criteria for accreditation of medical imaging labs: Shardul Nautiyal, Mumbai Friday, January ...

PulseSight Therapeutics completes patient enrolment in phase I trial of PST-611 to treat dry AMD/geographic atrophy: Paris, France Friday, January 23, 2026, 18:00 Hrs [IST] PulseS ...

Akums strengthens presence in regulated markets with EU GMP approvals for 2 Haridwar plants: Our Bureau, Bengaluru Friday, January 23, 2026, 17:45 Hrs [IST] Akums Drugs & Pharmace ...

The Government of Telangana, India unveiled its Next-Gen Life Sciences Policy 2026–30 at the World Economic Forum Annual Meeting in Davos, signalling the State’s intent to play a far more ...

Syngene International in Q3 revenues dip registering Rs. 932 crore and PAT slides by 44 per cent: Our Bureau, Bengaluru Friday, January 23, 2026, 12:15 Hrs [IST] Syngene Internati ...

Onward Medical completes two additional BCI implants paired with spinal cord stimulation technology to restore thought-driven movement: Eindhoven, the Netherlands Friday, January ...

Galderma provides update on arbitration case regarding neuromodulator research and development partnership: Zug, Switzerland Friday, January 23, 2026, 16:00 Hrs [IST] Galderma, th ...

The Committee for Control and Supervision of Experiments on Animals (CCSEA), a statutory Committee of Department of Animal Husbandry and Dairying (DAHD) constituted under the Prevention of Cruelty to ...

Daiichi Sankyo has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of ...

Lupin receives highest ESG rating from CDP for Climate Change and Water Security: Our Bureau, Mumbai Friday, January 23, 2026, 14:30 Hrs [IST] Global pharma major Lupin Limited (L ...

US FDA grants Orphan Drug Designation to BlueRock Therapeutics’ investigational cell therapy OpCT-001 to treat retinitis pigmentosa: Berlin, Germany Friday, January 23, 2026, 09 ...